You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村上調康方生物-B(09926.HK)目標價至46.04元 評級「買入」
阿思達克 12-07 10:14
野村發表報告指,上調康方生物-B(09926.HK)目標價,由31.54元升至46.04元,評級為「買入」。 該行指,康方生物與Summit Therapeutics Inc.訂立合作及許可協議。Summit將獲授於美國、加拿大、歐洲及日本開發及商業化其突破性雙特異性抗體依沃西(PD-1/VEGF,AK112)的獨家許可權。作為交換條件,公司獲得5億美元的首付款,公司最高可45億美元的商業付款,包括產品開發、註冊及商業化里程碑款項。這筆交易的價值是中國生物技術專利許可歷史上最大的交易之一。同時,集團亦將獲得依沃西產品銷售淨額的低雙位數百分比的提成,作為特許權使用費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account